Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer [0.03%]
第二代表皮生长因子受体酪氨酸激酶抑制剂治疗非小细胞肺癌患者的疗效和安全性系统评价及meta分析
Thierry Berghmans,Myriam Remmelink,Ahmad Awada
Thierry Berghmans
Targeted therapies are nowadays a treatment option in metastatic non-small cell lung cancer, for which oncogenic drivers have been identified. The epidermal growth factor-receptor tyrosine kinase inhibitors gefitinib and erlotinib, are the ...
Lung cancer in women [0.03%]
女性肺癌
Raúl Barrera-Rodriguez,Jorge Morales-Fuentes
Raúl Barrera-Rodriguez
Recent biological advances in tumor research provide clear evidence that lung cancer in females is different from that in males. These differences appear to have a direct impact on the clinical presentation, histology, and outcomes of lung ...
Association of p21 Ser31Arg and p53 Arg72Pro polymorphisms with lung cancer risk in CAPUA study [0.03%]
CAPUA研究中p21Ser31Arg和p53Arg72Pro多态性与肺癌风险的关系
Ana Souto-García,Ana Fernández-Somoano,Teresa Pascual et al.
Ana Souto-García et al.
Background: The aim of this study was to investigate how Ser31Arg polymorphisms in p21 may modify lung cancer susceptibility. Because p21 is the major downstream mediator of p53, we analyzed the combined effect of two pol...
MET targeted therapy for lung cancer: clinical development and future directions [0.03%]
肺癌MET靶向治疗的临床开发及未来方向
Yan Feng,Patrick C Ma
Yan Feng
MET, the receptor for hepatocyte growth factor, has been identified as a novel promising target in various human malignancies, including lung cancer. Research studies have demonstrated that MET signaling plays important physiologic roles in...
Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis [0.03%]
希腊培美曲塞治疗二线晚期非小细胞肺癌的经济评估：成本最小化分析
V F Fragoulakis,A G Pallis,D K Kaitelidou et al.
V F Fragoulakis et al.
Objectives: An economic evaluation was conducted in conjunction with a prospective, multicenter, randomized trial, to compare pemetrexed with erlotinib in pretreated patients with metastatic non-small cell lung cancer (NS...
Mara B Antonoff,Jonathan D&#x;Cunha
Mara B Antonoff
In this review, the authors aim to provide an overview of current molecular targeted therapies for NSCLC, to propose an algorithm for clinical application of presently available treatment strategies, and to identify future directions for th...
Eloisa Jantus-Lewintre,Marta Usó,Elena Sanmartín et al.
Eloisa Jantus-Lewintre et al.
Patients at risk for lung cancer may have subclinical disease for years before presentation. The diagnosis of this disease is primarily based on symptoms, and detection often occurs after curative intervention is no longer possible. At pres...
A pilot study of a metronomic chemotherapy regimen with weekly low-dose docetaxel for previously treated non-small cell lung cancer [0.03%]
每周小剂量多西他赛肺动脉化疗治疗晚期非小细胞肺癌的临床研究试点项目
Takashi Yokoi,Takeshi Tamaki,Toshiki Shimizu et al.
Takashi Yokoi et al.
Background: Low-dose metronomic (LDM) chemotherapy is a novel approach that involves frequent administration of a low dose of chemotherapeutic agent without a long interval. ...
Single nucleotide polymorphisms as susceptibility, prognostic, and therapeutic markers of nonsmall cell lung cancer [0.03%]
非小细胞肺癌的易感、预后和治疗标记的单核苷酸多态性研究
Shanbeh Zienolddiny,Vidar Skaug
Shanbeh Zienolddiny
Lung cancer is a major public health problem throughout the world. Among the most frequent cancer types (prostate, breast, colorectal, stomach, lung), lung cancer is the leading cause of cancer-related deaths worldwide. Among the two major ...
Nimotuzumab, a novel monoclonal antibody to the epidermal growth factor receptor, in the treatment of non-small cell lung cancer [0.03%]
抗人表皮生长因子受体单克隆抗体尼莫单抗治疗非小细胞肺癌研究
Masayuki Takeda,Isamu Okamoto,Yasumasa Nishimura et al.
Masayuki Takeda et al.
The epidermal growth factor receptor (EGFR) is a promising therapeutic target in non-small cell lung cancer, and several therapeutic agents that target this receptor, including EGFR tyrosine kinase inhibitors and monoclonal antibodies to EG...